stars 1 stars 2 stars 3

Actinium-225 supply cannot keep pace with growing demand. We are solving this at scale. Transmutex is developing HI-BEAM to produce actinium-225, a radioactive isotope used in targeted cancer treatments, at industrial scale. Our technology combines a high-energy cyclotron, thorium targets and proprietary extraction technology. It uses abundant thorium-232, without relying on highly radioactive material or legacy nuclear waste inventories. For isotope supply, partnerships or investment, contact info@transmutex.com.

TRANSMUTEX Questions

Franklin Servan-Schreiber is the Co-Founder, Chairman and CEO of TRANSMUTEX.

47 people are employed at TRANSMUTEX.

TRANSMUTEX is based in Vernier, Geneva.

Top TRANSMUTEX Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users